Literature DB >> 18688088

p70 S6 kinase and tau in Alzheimer's disease.

Jin-Jing Pei1, Cecilia Björkdahl, Haiyan Zhang, Xinwen Zhou, Bengt Winblad.   

Abstract

The 70-kDa S6 kinase (p70S6K) is a Ser/Thr (S/T)-directed kinase that plays a crucial role in cell growth, cell differentiation, and cell cycle control. This article presented evidence that supports both toxic and protective roles of p70S6K activity towards tau in Alzheimer's disease (AD) brains. The p70S6K can phosphorylate tau at S262, S214, and T212 sites. Phosphorylation at these sites might release tau from microtubules, resulting in microtubule disruption. Evidence also suggests that p70S6K regulates the translation of tau mRNA by phosphorylating the 40S ribosomal protein S6. The extracellular amyloid-beta deposition in AD brains could be a causative factor that activates p70S6K. We hypothesized that amyloid-beta deposition activates p70S6K whose anti-apoptotic property subsequently keeps neurons from entering into the apoptotic process. This process provides the opportunity for the newly synthesized tau to be phosphorylated by p70S6K and by other tau kinases. This hyperphosphorylated tau then aggregates and is progressively deposited in neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688088     DOI: 10.3233/jad-2008-14405

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  38 in total

1.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.

Authors:  Antonella Caccamo; Smita Majumder; Arlan Richardson; Randy Strong; Salvatore Oddo
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

2.  Functional role of RNA polymerase II and P70 S6 kinase in KCl withdrawal-induced cerebellar granule neuron apoptosis.

Authors:  Jaya Padmanabhan; Kristy R Brown; Amelia Padilla; Michael L Shelanski
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

3.  Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism.

Authors:  Antonella Caccamo; Monica A Maldonado; Smita Majumder; David X Medina; Walter Holbein; Andrea Magrí; Salvatore Oddo
Journal:  J Biol Chem       Date:  2011-01-25       Impact factor: 5.157

Review 4.  Targeting the mTOR signaling network for Alzheimer's disease therapy.

Authors:  Chong Wang; Jin-Tai Yu; Dan Miao; Zhong-Chen Wu; Meng-Shan Tan; Lan Tan
Journal:  Mol Neurobiol       Date:  2013-07-14       Impact factor: 5.590

5.  The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.

Authors:  Caitriona M Long-Smith; Sean Manning; Paula L McClean; Meghan F Coakley; Domhnall J O'Halloran; Christian Holscher; Cora O'Neill
Journal:  Neuromolecular Med       Date:  2012-09-21       Impact factor: 3.843

6.  Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease.

Authors:  Antonella Caccamo; Ramona Belfiore; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2018-04-05       Impact factor: 4.673

7.  mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease.

Authors:  Andrés Norambuena; Horst Wallrabe; Lloyd McMahon; Antonia Silva; Eric Swanson; Shahzad S Khan; Daniel Baerthlein; Erin Kodis; Salvatore Oddo; James W Mandell; George S Bloom
Journal:  Alzheimers Dement       Date:  2016-09-29       Impact factor: 21.566

8.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

9.  mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.

Authors:  Antonella Caccamo; Andrea Magrì; David X Medina; Elena V Wisely; Manuel F López-Aranda; Alcino J Silva; Salvatore Oddo
Journal:  Aging Cell       Date:  2013-03-24       Impact factor: 9.304

10.  Combination of PKCε Activation and PTP1B Inhibition Effectively Suppresses Aβ-Induced GSK-3β Activation and Tau Phosphorylation.

Authors:  Takeshi Kanno; Ayako Tsuchiya; Akito Tanaka; Tomoyuki Nishizaki
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.